TipRanks
Bruker Corp (CH:BKD)
:BKD
Switzerland Market
BKD
Bruker
RESEARCH TOOLSreports

Bruker (BKD) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

BKD Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
6 Buy
3 Hold
1 Sell
Based on 10 analysts giving stock ratings to
Bruker
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BKD Stock 12 Month Forecast

Average Price Target

―
Based on 10 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is CHF50.85 with a high forecast of CHF66.57 and a low forecast of CHF41.61. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF66.57Average Price TargetCHF50.85Lowest Price TargetCHF41.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:BKD
Luke Sergott
Barclays
Barclays
CHF48.27→CHF58.25
Buy
―
Reiterated
10/07/26
Barclays Reaffirms Their Buy Rating on Bruker (BRKR)
Goldman Sachs Analyst forecast on CH:BKD
Evie Koslosky
Goldman Sachs
Goldman Sachs
CHF33.29→CHF41.61
Sell
―
Reiterated
10/05/26
Goldman Sachs Reaffirms Their Sell Rating on Bruker (BRKR)
Guggenheim Analyst forecast on CH:BKD
Subbu Nambi
Guggenheim
Guggenheim
CHF58.25→CHF59.92
Buy
―
Reiterated
10/01/26
Bruker price target raised to $72 from $70 at GuggenheimBruker price target raised to $72 from $70 at Guggenheim
Leerink Partners Analyst forecast on CH:BKD
Puneet Souda
Leerink Partners
Leerink Partners
CHF49.93→CHF66.57
Buy
―
Reiterated
09/29/26
Bruker (BRKR) Receives a Buy from Leerink Partners
J.P. Morgan Analyst forecast on CH:BKD
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF54.09→CHF49.93
Buy
―
Reiterated
08/06/26
J.P. Morgan Remains a Buy on Bruker (BRKR)
Stifel Nicolaus Analyst forecast on CH:BKD
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
CHF37.45→CHF41.61
Hold
―
Reiterated
08/05/26
Bruker price target raised to $50 from $45 at StifelBruker price target raised to $50 from $45 at Stifel
Bank of America Securities Analyst forecast on CH:BKD
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Bruker (BRKR), Arvinas Holding Company (ARVN)
Citi Analyst forecast on CH:BKD
Patrick B Donnelly
Citi
Citi
CHF49.93→CHF44.1
Hold
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
Wells Fargo Analyst forecast on CH:BKD
Evan Stampler
Wells Fargo
Wells Fargo
CHF45.77
Buy
―
Reiterated
08/05/26
Bruker (BRKR) Receives a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:BKD
Kyle Boucher
TD Cowen
TD Cowen
CHF49.93
Hold
―
Reiterated
08/04/26
Hold Rating Maintained on Bruker as Mixed End-Market Trends and Back-Half-Weighted Outlook Keep Risk/Reward Balanced
Wolfe Research Analyst forecast on CH:BKD
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
06/01/26
Bruker assumed at Peer Perform from Outperform at Wolfe ResearchBruker assumed at Peer Perform from Outperform at Wolfe Research
RBC Capital Analyst forecast on CH:BKD
Dan Leonard
RBC Capital
RBC Capital
CHF33.29→CHF37.45
Hold
―
Assigned
05/07/26
Bruker price target raised to $45 from $40 at UBSBruker price target raised to $45 from $40 at UBS
Jefferies Analyst forecast on CH:BKD
Tycho Peterson
Jefferies
Jefferies
CHF45.77→CHF41.61
Buy
―
Reiterated
02/12/26
Bruker price target lowered to $50 from $55 at JefferiesBruker price target lowered to $50 from $55 at Jefferies
UBS Analyst forecast on CH:BKD
Doug Schenkel
UBS
UBS
CHF49.93
Buy
―
Upgraded
12/10/25
Bruker upgraded to Outperform from Peer Perform at Wolfe ResearchBruker upgraded to Outperform from Peer Perform at Wolfe Research
Rothschild & Co Redburn Analyst forecast on CH:BKD
Natalya Davies
Rothschild & Co Redburn
Rothschild & Co Redburn
CHF49.93
Buy
―
Reiterated
11/20/25
Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:BKD
Luke Sergott
Barclays
Barclays
CHF48.27→CHF58.25
Buy
―
Reiterated
10/07/26
Barclays Reaffirms Their Buy Rating on Bruker (BRKR)
Goldman Sachs Analyst forecast on CH:BKD
Evie Koslosky
Goldman Sachs
Goldman Sachs
CHF33.29→CHF41.61
Sell
―
Reiterated
10/05/26
Goldman Sachs Reaffirms Their Sell Rating on Bruker (BRKR)
Guggenheim Analyst forecast on CH:BKD
Subbu Nambi
Guggenheim
Guggenheim
CHF58.25→CHF59.92
Buy
―
Reiterated
10/01/26
Bruker price target raised to $72 from $70 at GuggenheimBruker price target raised to $72 from $70 at Guggenheim
Leerink Partners Analyst forecast on CH:BKD
Puneet Souda
Leerink Partners
Leerink Partners
CHF49.93→CHF66.57
Buy
―
Reiterated
09/29/26
Bruker (BRKR) Receives a Buy from Leerink Partners
J.P. Morgan Analyst forecast on CH:BKD
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF54.09→CHF49.93
Buy
―
Reiterated
08/06/26
J.P. Morgan Remains a Buy on Bruker (BRKR)
Stifel Nicolaus Analyst forecast on CH:BKD
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
CHF37.45→CHF41.61
Hold
―
Reiterated
08/05/26
Bruker price target raised to $50 from $45 at StifelBruker price target raised to $50 from $45 at Stifel
Bank of America Securities Analyst forecast on CH:BKD
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/05/26
Analysts Are Bullish on These Healthcare Stocks: Bruker (BRKR), Arvinas Holding Company (ARVN)
Citi Analyst forecast on CH:BKD
Patrick B Donnelly
Citi
Citi
CHF49.93→CHF44.1
Hold
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
Wells Fargo Analyst forecast on CH:BKD
Evan Stampler
Wells Fargo
Wells Fargo
CHF45.77
Buy
―
Reiterated
08/05/26
Bruker (BRKR) Receives a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:BKD
Kyle Boucher
TD Cowen
TD Cowen
CHF49.93
Hold
―
Reiterated
08/04/26
Hold Rating Maintained on Bruker as Mixed End-Market Trends and Back-Half-Weighted Outlook Keep Risk/Reward Balanced
Wolfe Research Analyst forecast on CH:BKD
Michael Polark
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
06/01/26
Bruker assumed at Peer Perform from Outperform at Wolfe ResearchBruker assumed at Peer Perform from Outperform at Wolfe Research
RBC Capital Analyst forecast on CH:BKD
Dan Leonard
RBC Capital
RBC Capital
CHF33.29→CHF37.45
Hold
―
Assigned
05/07/26
Bruker price target raised to $45 from $40 at UBSBruker price target raised to $45 from $40 at UBS
Jefferies Analyst forecast on CH:BKD
Tycho Peterson
Jefferies
Jefferies
CHF45.77→CHF41.61
Buy
―
Reiterated
02/12/26
Bruker price target lowered to $50 from $55 at JefferiesBruker price target lowered to $50 from $55 at Jefferies
UBS Analyst forecast on CH:BKD
Doug Schenkel
UBS
UBS
CHF49.93
Buy
―
Upgraded
12/10/25
Bruker upgraded to Outperform from Peer Perform at Wolfe ResearchBruker upgraded to Outperform from Peer Perform at Wolfe Research
Rothschild & Co Redburn Analyst forecast on CH:BKD
Natalya Davies
Rothschild & Co Redburn
Rothschild & Co Redburn
CHF49.93
Buy
―
Reiterated
11/20/25
Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ASNDAscendis Pharma
AXGNAxoGen
ONCBeOne Medicines
BDTXBlack Diamond Therapeutics
RPRXRoyalty Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

3 Months
Luke SergottBarclays
Success Rate
9/16 ratings generated profit
56%
Average Return
+2.96%
Copying Luke Sergott's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +2.96% per trade.
1 Year
Luke SergottBarclays
Success Rate
12/16 ratings generated profit
75%
Average Return
+23.86%
Copying Luke Sergott's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +23.86% per trade.
2 Years
Luke SergottBarclays
Success Rate
15/16 ratings generated profit
94%
Average Return
+38.75%
Copying Luke Sergott's trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +38.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BKD Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
7
6
10
7
9
Hold
6
7
6
6
4
Sell
0
2
2
3
2
Strong Sell
0
0
0
0
0
total
13
15
18
16
15
In the current month, BKD has received 9 Buy Ratings, 4 Hold Ratings, and 2 Sell Ratings. BKD average Analyst price target in the past 3 months is 50.85.
Each month's total comprises the sum of three months' worth of ratings.

BKD Financial Forecast

BKD Earnings Forecast

Next quarter’s earnings estimate for BKD is CHF0.35 with a range of CHF0.32 to CHF0.37. The previous quarter’s EPS was CHF0.41. BKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.
Next quarter’s earnings estimate for BKD is CHF0.35 with a range of CHF0.32 to CHF0.37. The previous quarter’s EPS was CHF0.41. BKD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.

BKD Sales Forecast

Next quarter’s sales forecast for BKD is CHF718.72M with a range of CHF705.43M to CHF723.54M. The previous quarter’s sales results were CHF696.54M. BKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.
Next quarter’s sales forecast for BKD is CHF718.72M with a range of CHF705.43M to CHF723.54M. The previous quarter’s sales results were CHF696.54M. BKD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BKD has Performed in-line its overall industry.

BKD Stock Forecast FAQ

What is CH:BKD’s average 12-month price target, according to analysts?
Based on analyst ratings, Bruker Corp’s 12-month average price target is 50.85.
    What is CH:BKD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:BKD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Bruker Corp a Buy, Sell or Hold?
        Bruker Corp has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 1 sell ratings.
          What is Bruker Corp’s share price target?
          The average share price target for Bruker Corp is 50.85. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF66.57 ,and the lowest forecast is CHF41.61. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Bruker Corp?
            Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of Bruker Corp?
              To buy shares of CH:BKD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.